All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 4th European CAR T-Cell Meeting, the ALL Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We asked, how do CAR T-cell recipients respond to COVID-19 vaccination?
How do CAR T-cell recipients respond to COVID-19 vaccination?
In this video, Nagler discusses chimeric antigen receptor (CAR) T-cell therapy (CAR-T). He also highlights the challenges that COVID-19 has caused to CAR-T and the implications for patients with; Non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies
Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary recommendations issued by the National Comprehensive...
Use of ruxolitinib in patients with severe COVID-19
Colleagues from the RUXO-COVID Study Group have recently published the findings of a prospective observational study in Leukemia, in which they assessed response to ruxolitinib treatment in 34...
Subscribe to get the best content related to ALL delivered to your inbox